Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

1701 - Immunogenicity and optimal timing of 13-valent pneumococcal conjugate vaccination during adjuvant chemotherapy in gastric and colorectal cancer : A randomized controlled trial


28 Sep 2019


Poster Display session 1


Supportive Care and Symptom Management

Tumour Site


Wonyoung Choi


Annals of Oncology (2019) 30 (suppl_5): v718-v746. 10.1093/annonc/mdz265


W. Choi1, J.G. Kim2, S. beom3, J.E. Hwang1, H. Shim1, S. Cho1, M. Shin4, S. Jung5, I. Chung1, J.Y. Song6, W.K. Bae1

Author affiliations

  • 1 Medical Oncology, Chonnam National University Hwasun Hospital, 58128 - Jeonnam/KR
  • 2 Oncology, Kyungpook National University Hospital, 700-721 - Daegu/KR
  • 3 Medical Oncology, Yonsei Cancer Center, Seoul/KR
  • 4 Department Of Preventive Medicine, Chonnam National University Medical School, 58128 - Hwasun/KR
  • 5 Department Of Biostatistics And Bioinformatics, Duke University, 27710 - Durham/US
  • 6 Division Of Infectious Diseases, Department Of Internal Medicine, Korea University College of Medicine, 08308 - Seoul/KR


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1701


Pneumococcal vaccination (PCV13) is recommended to cancer patients undergoing systemic chemotherapy. However, the optimal time interval between vaccine administration and initiation of chemotherapy has been little studied in adult patients with solid malignancies.


We conducted a prospective randomized controlled trial to evaluate whether administering PCV13 on the first day of chemotherapy is non-inferior to vaccinating two weeks prior to chemotherapy initiation. Patients were randomly assigned to two study arms, and serum samples were collected at baseline and 4 weeks after vaccination to analyze the serologic response against Streptococcus pneumonia using a multiplexed opsonophagocytic killing assay.


Of the 92 patients who underwent randomization, 43 patients in Arm A (vaccination 2 weeks before chemotherapy) and 44 patients in Arm B (vaccination on the first day of chemotherapy) were analyzed. Immunogenicity was assessed by geometric mean and fold-increase of post-vaccination titers, seroprotection rates (percentage of patients with post-vaccination titers > 1:64), and seroconversion rates (percentage of patients with > four-fold increase in post-vaccination titers). Serologic responses to PCV13 did not differ significantly between the two study arms according to all three types of assessments.


The overall antibody response to PCV13 is adequate in patients with gastric and colorectal cancer during adjuvant chemotherapy, and no significant difference was found when patients were vaccinated two weeks before or on the day of chemotherapy initiation.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

The authors.


National Research Foundation of Korea (NRF), Ministry of Health and Welfare of Korea.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.